ArticleStem cell research & therapy2013
Mesenchymal stem cells protect podocytes from apoptosis induced by high glucose via secretion of epithelial growth factor.
Article in Stem cell research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Efficacy of stem cell therapy for diabetic kidney disease: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Mesenchymal Stem Cells Polarize Macrophages to an Anti-Inflammatory Phenotype to Ameliorate Diabetic Nephropathy.Stem cells international · 2026Article
- Mesenchymal stem cells: a potential therapeutic strategy for IgA nephropathy.Frontiers in pharmacology · 2026Review
- Association of soluble urokinase plasminogen activator receptor and epidermal growth factor with histopathological findings of kidney biopsy: a single-center study.BMC nephrology · 2025Article
- Progress in the application of mesenchymal stem cells to attenuate apoptosis in diabetic kidney disease.World journal of diabetes · 2025Review
- Umbilical Cord Mesenchymal Stem Cells Attenuate Podocyte Injury in Diabetic Nephropathy Rats by Inhibiting Angpltl4/IntegrinJournal of diabetes research · 2025Article
- Mitigating hemoglobin-induced nephropathy: ApoHb-hp protection of podocytes.Physiological reports · 2024Article
- Review
- Identification of key immune-related genes and potential therapeutic drugs in diabetic nephropathy based on machine learning algorithms.BMC medical genomics · 2024Article
- Intravenous injection of human umbilical cord-derived mesenchymal stem cells ameliorates not only blood glucose but also nephrotic complication of diabetic rats through autophagy-mediated anti-senescent mechanism.Stem cell research & therapy · 2023Article
- Extracellular Vesicles Released from Stem Cells as a New Therapeutic Strategy for Primary and Secondary Glomerulonephritis.International journal of molecular sciences · 2022Review
- Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- An overview of the efficacy and signaling pathways activated by stem cell-derived extracellular vesicles in diabetic kidney disease.Frontiers in endocrinology · 2022Review
- Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte.Journal of cellular and molecular medicine · 2021Article
- Therapeutic Potential of Mesenchymal Stem Cells in a Pre-Clinical Model of Diabetic Kidney Disease and Obesity.International journal of molecular sciences · 2021Article
- Ultrasound‑targeted microbubble destruction‑mediated Galectin‑7‑siRNA promotes the homing of bone marrow mesenchymal stem cells to alleviate acute myocardial infarction in rats.International journal of molecular medicine · 2021Article
- The Multi-Therapeutic Role of MSCs in Diabetic Nephropathy.Frontiers in endocrinology · 2021Review
- Epidermal Growth Factor Protects Against High Glucose-Induced Podocyte Injury Possibly via Modulation of Autophagy and PI3K/AKT/mTOR Signaling Pathway Through DNA Methylation.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Transplantation of mesenchymal stem cells preserves podocyte homeostasis through modulation of parietal epithelial cell activation in adriamycin-induced mouse kidney injury model.Histology and histopathology · 2020Article
- Concise review: current trends on applications of stem cells in diabetic nephropathy.Cell death & disease · 2020Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe apoptosis and subsequent injury of podocytes plays a pathogenic role in diabetic nephropathy (DN). Mesenchymal stem cells (MSCs) are promising therapeutic cells for preventing apoptosis and reducing cellular injury. Our previous study found that MSCs could protect kidneys from diabetes-induced injury without obvious engraftment. So we evaluated the effects of human adipose-derived MSCs (hAd-MSCs) on podocytic apoptosis and injury induced by high glucose (HG) and the underlying mechanisms.
methodsWe used flow cytometry, Western blot and confocal fluorescence microscopy to study podocytic apoptosis and injury induced by HG at 24 hours, 48 hours, and 72 hours in the presence or absence of MSC-conditioned medium (CM). An antibody-based cytokine array was used to identify the mediating factor, which was verified by adding the neutralizing antibody (NtAb) to block its function or adding the recombinant cytokine to the medium to induce its function.
resultshAd-MSC-CM reduced podocytic apoptosis in a dose-dependent manner, decreased the expression of podocytic cleaved caspase-3, and prevented the reduced expression and maintained the normal arrangement of podocytic synaptopodin and nephrin. However, human embryonic lung cell (Wi38)-CM failed to ameliorate podocytic apoptosis or injury. Twelve cytokines with concentration ratios (MSC-CM/Wi38-CM) >10-fold were identified. Epithelial growth factor (EGF) was singled out for its known ability to prevent apoptosis. Recombinant human EGF (rhEGF) prevented podocytic apoptosis and injury similarly to hAd-MSC-CM but, upon blockade of EGF, the beneficial effect of hAd-MSC-CM decreased dramatically.
conclusionshAd-MSCs prevent podocytic apoptosis and injury induced by HG, mainly through secreting soluble EG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.